10-K: Hoth Therapeutics Reports Widened Losses, Going Concern Doubts

Hoth Therapeutics, Inc. reported a significant increase in net loss for 2025, alongside a going concern warning from its auditors, despite progress in its clinical pipeline and substantial capital raises.

Summary

• Hoth Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $12.5 million for the year ended December 31, 2025, a substantial increase from $8.2 million in 2024.
• The company's accumulated deficit grew to $72.9 million as of December 31, 2025, up from $60.4 million in 2024.
• Research and development expenses increased to $5.9 million in 2025 from $3.2 million in 2024, driven by manufacturing and clinical activities for HT-001, HT-KIT, and the acquisition of patent applications.
• General and administrative expenses rose to $6.4 million in 2025 from $5.0 million in 2024, primarily due to increased compensation and professional fees.
• Cash and cash equivalents decreased to $6.2 million as of December 31, 2025, from $7.0 million in 2024, with net cash used in operating activities increasing to $9.8 million from $7.0 million.
• The company raised approximately $4.1 million in net proceeds from common stock issuance through an At The Market (ATM) Offering Agreement and $5.6 million from warrant exercises in 2025.
• HT-001, a topical formulation for cancer drug side effects, received EMA approval in January 2026 to expand its Phase 2a clinical trial to Europe and has shown positive interim preliminary clinical results.
• HT-KIT, for mast-cell derived cancers and anaphylaxis, has Orphan Drug Designation from the FDA and is advancing IND-enabling activities following positive FDA feedback on its pre-IND meeting request.
• HT-ALZ, for Alzheimer's and neuroinflammatory diseases, was granted a U.S. patent in November 2024 and is undergoing formulation development and additional animal studies after positive preclinical results.
• The company acquired three provisional patent applications for additional HT-001 indications in January 2025 and executed proposals for proof-of-concept studies in January 2026.
• Hoth Therapeutics holds crypto assets valued at $191,367 as of December 31, 2025, incurring an unrealized loss of $108,633, and liquidated all crypto holdings by February 5, 2026.
• The independent registered public accounting firm expressed substantial doubt about the company's ability to continue as a going concern, as existing cash is not believed to be sufficient for the next 12 months.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a low sentiment score due to the significant increase in net losses, a critical going concern warning from auditors, and explicit management statements about insufficient cash for the next 12 months. While there is pipeline progress and successful capital raises, the financial instability and heavy reliance on future financing for survival outweigh the early-stage clinical advancements.

Positives

• HT-001 received EMA approval in January 2026 to expand its Phase 2a clinical trial to Spain, Poland, and Hungary, indicating international regulatory progress.
• HT-001 has achieved positive interim preliminary clinical results from its open label cohort and is actively enrolling in both open label and double-blind randomized cohorts.
• HT-KIT has Orphan Drug Designation from the FDA for mastocytosis, which provides potential financial incentives and market exclusivity if approved.
• FDA feedback on HT-KIT's pre-IND meeting request supports advancing IND-enabling activities as planned.
• HT-ALZ was granted a U.S. patent in November 2024 for treating and preventing Alzheimer's and other neuroinflammatory diseases, strengthening its intellectual property.
• HT-ALZ has shown positive initial preclinical results from a chronic dosing study in mice, indicating potential efficacy.
• HT-VA studies were completed with positive initial results in January 2026, suggesting potential for a new obesity treatment.
• The company successfully raised approximately $9.7 million in net proceeds from equity issuances and warrant exercises in 2025, demonstrating access to capital markets.

Negatives

• Net loss significantly widened to $12.5 million in 2025 from $8.2 million in 2024, indicating increased operational losses.
• The company has generated no revenue from commercial sales since inception and expects to continue operating at a net loss for several years.
• Accumulated deficit increased to $72.9 million as of December 31, 2025, highlighting significant historical losses.
• Cash and cash equivalents decreased to $6.2 million as of December 31, 2025, from $7.0 million in 2024, indicating a declining cash position.
• Net cash used in operating activities increased to $9.8 million in 2025 from $7.0 million in 2024, reflecting a higher cash burn rate.
• The independent registered public accounting firm expressed substantial doubt about the company's ability to continue as a going concern, citing recurring losses and negative cash flows.
• Management does not believe existing cash is sufficient to fund operations for the next 12 months from the financial statement issuance date.
• The company incurred an unrealized loss of $108,633 on crypto assets in 2025, and subsequently liquidated all holdings by February 5, 2026.
• Significant shareholder dilution occurred with 2,782,309 shares issued through the ATM agreement in 2025 and 756,187 shares issued in early 2026, in addition to 3,750,000 shares from warrant exercises in 2025.

Risks

• No revenue from commercial sales to date and future profitability is uncertain, requiring substantial additional capital.
• The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern, which may hinder future financing.
• Dependence on the clinical success of licensed products and technologies; failure to generate revenues from these could limit shareholder value.
• The marketing approval process is lengthy, time-consuming, and inherently unpredictable; inability to obtain marketing approval would substantially harm the business.
• Substantial delays in completing clinical studies may occur, requiring additional costs or failing to demonstrate adequate safety and efficacy.
• Difficulty in identifying and recruiting suitable patients for clinical trials, and potential delays from protocol modifications.
• Reliance on third parties to conduct clinical trials, assist with preclinical development, and for manufacturing and marketing; non-performance could prevent regulatory approval or commercialization.
• Reliance on single-sourced manufacturing with WuXi AppTec for HT-KIT, which increases risk due to potential problems or delays, and exposure to U.S. legislation like the BIOSECURE Act.
• Even if products are approved, failure to comply with ongoing FDA regulations or unanticipated problems could lead to restrictions or market withdrawal.
• Revenue stream will depend upon third-party reimbursement, which is increasingly limited and uncertain.
• Products will face significant competition from major biopharmaceutical companies, academic institutions, and smaller companies with greater resources.
• Failure to comply with healthcare regulations could lead to substantial enforcement actions, including civil and criminal penalties.
• Business depends on securing and protecting critical intellectual property; patent positions are highly uncertain and involve complex legal and factual questions.
• Reliance on licenses granted by various licensors; inadequate defense of these licenses by licensors could harm the business.
• Expansion through acquisition of rights to new drug candidates could disrupt business, harm financial condition, and dilute current shareholders.
• Product liability claims, if uninsured or exceeding coverage, could result in substantial damage awards.
• Significant disruptions of information technology systems or breaches of data security could adversely affect the business and expose sensitive data.
• Any international operations undertaken may subject the company to risks inherent with operations outside of the United States.
• Unstable market and economic conditions and adverse developments with respect to financial institutions may have serious adverse consequences on business, financial condition, and stock price.
• Future sales and issuances of securities could result in additional dilution of percentage ownership and cause share price to fall.
• No intention to pay cash dividends; returns will be limited to share value appreciation.
• Inability to maintain listing on The Nasdaq Capital Market could adversely affect stock price and liquidity.
• Anti-takeover effects in Articles of Incorporation and Bylaws could discourage or delay a change in control.
• Exclusive forum provision in Bylaws could limit shareholders' ability to obtain a favorable judicial forum for disputes.
• Financial reporting obligations as a public company are expensive and time-consuming, requiring substantial management time.
• Failure to maintain effective internal controls could cause investors to lose confidence and adversely affect stock price.

Future Outlook

Hoth Therapeutics expects research and development activities and general and administrative expenses to increase in future periods as it continues to develop existing product candidates, potentially acquires new ones, and supports business development. The company anticipates needing substantial additional capital to fund operations, clinical trials, and commercialization efforts, as current cash is not sufficient for the next 12 months. Future funding may involve dilutive equity issuances or debt financing. The company also faces ongoing uncertainty regarding regulatory approval timelines, market acceptance, and the impact of evolving healthcare reforms on pricing and reimbursement.

Management Comments

• We expect our research and development activities to increase as we develop our existing product candidates and potentially acquire new product candidates, reflecting increasing costs associated with employee-related expenses, in-licensed products, CROs, clinical trial materials, and regulatory approvals.
• We anticipate that our general and administrative expenses will increase in future periods, reflecting continued and increasing costs associated with support of our research and development activities, stock compensation, business development, and increased professional fees related to regulatory requirements.
• We do not believe that our existing cash as of December 31, 2025 will enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from the date that our consolidated financial statements are available to be issued.
• We will require significant amounts of capital to sustain operations, and we will need to make the investments we need to execute our longer-term business plan to support new technologies and help advance innovation.

Industry Context

StockSavvy.ai notes that Hoth Therapeutics operates within the highly competitive and rapidly evolving biopharmaceutical industry, characterized by significant R&D investment, complex regulatory pathways, and intense intellectual property focus. The company's reliance on third-party manufacturers, particularly WuXi AppTec, exposes it to geopolitical risks and legislative impacts such as the BIOSECURE Act, which could restrict collaborations with certain Chinese biotechnology companies. The broader healthcare landscape, influenced by U.S. legislative changes like the Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act (OBBBA), continues to exert pressure on drug pricing and reimbursement, potentially limiting future revenues for companies like Hoth. The FDA's recent policy shift towards a 'one-trial requirement' for novel product candidates, while potentially streamlining approvals, also implies heightened scrutiny on trial quality and design, posing both opportunities and challenges for Hoth's pipeline. The company's strategy of pursuing the Section 505(b)(2) regulatory pathway for HT-ALZ and BioLexa aims to leverage existing data to reduce development time and cost, a common approach in drug repurposing within the industry.

Comparison to Industry Standards

• StockSavvy.ai observes that Hoth Therapeutics' financial position, marked by recurring losses and a going concern warning, is not uncommon for clinical-stage biopharmaceutical companies that have yet to commercialize products. However, the magnitude of the accumulated deficit ($72.9 million) and the increasing cash burn ($9.8 million in operating activities in 2025) indicate a significant capital requirement relative to its current cash reserves ($6.2 million).
• The company's reliance on ATM offerings and warrant exercises for liquidity is a standard financing mechanism for early-stage biotech firms, but the continuous dilution (shares outstanding nearly doubled in 2025) is a notable factor for investors.
• The progress of HT-001 to Phase 2a clinical trials and its expansion to Europe, along with HT-KIT's Orphan Drug Designation and advancement of IND-enabling activities, aligns with typical development milestones for a clinical-stage company. However, the lack of specific efficacy data beyond 'positive interim preliminary clinical results' for HT-001 makes a direct comparison to industry benchmarks challenging without more detailed disclosures.
• The pursuit of the 505(b)(2) pathway for HT-ALZ and BioLexa is a recognized strategy to accelerate drug development by leveraging existing safety and efficacy data, potentially reducing the time and cost compared to a full 505(b)(1) NDA, which is a common industry practice for repurposed drugs.
• The company's R&D expenditure increase in 2025 ($5.9 million) is consistent with a company actively progressing multiple drug candidates through preclinical and early clinical stages, though without revenue, this contributes directly to losses.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently aware of any legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on its business, financial condition, or operating results.

Related Party Transactions

• No transactions occurred during the fiscal years ended December 31, 2025 and 2024 that exceeded the lesser of $120,000 or 1% of average total assets, involving any directors, executive officers, or beneficial owners of more than 5% of capital stock, other than equity and other compensation arrangements disclosed elsewhere in the report.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing equity issuances to fund operations and product development.
• Shareholders are exposed to substantial financial risk due to recurring losses, negative cash flows, and the auditor's going concern warning.
• Employees may benefit from continued employment and equity incentive plans, but the company's financial instability poses a risk to long-term job security.
• Customers (future patients) could benefit from the development of new therapies for unmet medical needs, but the lengthy and uncertain drug development process means no immediate impact.
• Suppliers and contract manufacturing organizations (CMOs) are critical to the company's operations, and their performance directly impacts product development timelines and costs.
• Creditors face increased risk due to the company's substantial accumulated deficit and reliance on future financing to meet obligations.

Next Steps

• Continue to seek substantial additional capital through strategic relationships, public or private equity or debt financings, grants, or other arrangements.
• Advance IND-enabling activities for HT-KIT following FDA feedback.
• Optimize HT-ALZ formulation and conduct additional animal studies prior to pre-IND submission.
• Actively enroll patients in both open label and double-blind randomized cohorts for HT-001 Phase 2a clinical trial.
• Conduct proof-of-concept studies for the three new HT-001 indications acquired in January 2025.
• Continue preclinical studies for HT-004 in different animal models.
• Monitor and evaluate cybersecurity posture and performance on an ongoing basis through regular vulnerability scans, penetration tests, and threat intelligence feeds.
• Management will need to devote substantial time to ensure compliance with public company reporting obligations and corporate governance practices.

Key Dates

Recommendation

Hoth Therapeutics presents a high-risk investment profile. The company has no commercial revenue, a significantly widening net loss, and a substantial accumulated deficit. The explicit 'going concern' warning from its independent auditors, coupled with management's admission of insufficient cash for the next 12 months, indicates severe financial distress and a high probability of further dilutive capital raises or operational curtailment. While there is some progress in early-stage clinical trials and intellectual property, the path to commercialization is long, expensive, and highly uncertain. The increasing cash burn and reliance on external financing in an unpredictable market environment make the stock exceptionally speculative. A seasoned investor would view the current financial instability and the explicit going concern risk as paramount, warranting a strong sell recommendation to mitigate potential further capital loss.

Keywords

Biopharmaceutical, Clinical-stage, Drug development, SEC filing, 10-K, Hoth Therapeutics, HT-001, HT-KIT, HT-ALZ, BioLexa, HT-004, HT-VA, Cancer treatment, Alzheimer's disease, Atopic dermatitis, Obesity, Anaphylaxis, Asthma, Allergies, Orphan Drug Designation, FDA approval, EMA approval, Clinical trials, Preclinical studies, Intellectual property, Going concern, Net loss, Capital raise, ATM offering, Warrants, Share dilution, Regulatory risk, Biotech competition, Healthcare reform, Cybersecurity